PT  - JOURNAL ARTICLE
AU  - Misra-Press, Anita
ED  - Quoix, Elisabeth
TI  - TIME Trial
DP  - 2015 Jun 19
TA  - MD Conference Express
PG  - 11--13
VI  - 15
IP  - 8
4099  - http://mdc.sagepub.com/content/15/8/11.2.short
4100  - http://mdc.sagepub.com/content/15/8/11.2.full
AB  - The phase 2b results of the randomized, double-blind, placebo-controlled TIME study provide evidence of activity with TG4010, a therapeutic cancer vaccine, when added to first-line chemotherapy for stage IV non–small cell lung cancer, especially for nonsquamous histology and low levels of triple-positive activated lymphocytes. These data suggest that normal levels of triple-positive activated lymphocytes may be a predictive biomarker of TG4010 efficacy.